Maxim Group Has Lowered Expectations for scPharmaceuticals (NASDAQ:SCPH) Stock Price

scPharmaceuticals (NASDAQ:SCPH) had its price objective cut by equities research analysts at Maxim Group from $20.00 to $12.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Maxim Group’s target price indicates a potential upside of 298.01% from the company’s current price.

Separately, HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of scPharmaceuticals in a research note on Thursday.

scPharmaceuticals Stock Down 0.8 %

SCPH traded down $0.03 during midday trading on Thursday, hitting $3.02. 216,600 shares of the company’s stock traded hands, compared to its average volume of 394,029. scPharmaceuticals has a one year low of $2.75 and a one year high of $5.70. The company has a market cap of $150.87 million, a PE ratio of -1.59 and a beta of 0.40. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89. The stock’s fifty day simple moving average is $3.30 and its 200-day simple moving average is $3.81.

scPharmaceuticals (NASDAQ:SCPH) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.05. scPharmaceuticals had a negative net margin of 264.60% and a negative return on equity of 244.93%. The business had revenue of $12.15 million for the quarter, compared to the consensus estimate of $12.08 million. As a group, equities analysts anticipate that scPharmaceuticals will post -1.53 earnings per share for the current fiscal year.

Institutional Trading of scPharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets increased its stake in shares of scPharmaceuticals by 116.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock valued at $26,000 after acquiring an additional 3,101 shares during the last quarter. Legato Capital Management LLC acquired a new position in shares of scPharmaceuticals in the 4th quarter valued at approximately $37,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of scPharmaceuticals in the 4th quarter valued at approximately $38,000. Virtu Financial LLC acquired a new position in shares of scPharmaceuticals in the 3rd quarter valued at approximately $46,000. Finally, ProShare Advisors LLC acquired a new position in shares of scPharmaceuticals in the 4th quarter valued at approximately $48,000. 89.52% of the stock is owned by institutional investors.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.